NCT04438824View on ClinicalTrials.gov

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Well-differentiated/Dedifferentiated Liposarcoma
Interventions
DRUG

INCMGA00012

INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)

DRUG

Palbociclib

Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER